Tag Archives: immusant

ImmusanT Finds Celiac Disease Might Be Diagnosed With A Single Gluten Challenge

ImmusanT, a clinical-stage company developing Nexvax2®, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet, presented data at the 2017 International Celiac Disease Symposium (ICDS) in Delhi, India for a potential blood test that could detect celiac disease with a single gluten challenge. This blood test could also […]

Partnership with ImmusanT to Promote Phase 2 Clinical Trial of Nexvax2®, A Promising Celiac Disease Treatment

ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease […]

As Celiac and Gluten Sensitivities Gain Prominence, Drug Companies Race to Find Treatments

On behalf of our patient community, CDF has either directly invested or fought to secure investments in diagnostics, research, and treatment for celiac disease. We have always known that this was a serious disease with broad and often devastating impacts if left undiagnosed and/or untreated. Our 25 years of hard work continues to yield returns. […]